PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

BACKGROUND: On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors. Previous reports proved that the combinatorial antigen recognition strategy could improve the safety profile of CAR-T cells by targe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biomark Res
Asıl Yazarlar: Liao, Qibin, Mao, Yunyu, He, Huan, Ding, Xiangqing, Zhang, Xiaoyan, Xu, Jianqing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7607631/
https://ncbi.nlm.nih.gov/pubmed/33292688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00237-w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller